Amicus Therapeutics, Inc. (FOLD) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	634.2M	634.2M	528.3M	399.4M	329.2M
Cost of Revenue	76.7M	80.4M	52.9M	37.3M	38.6M
Gross Profit	557.5M	553.8M	475.4M	362.0M	290.6M
Operating Expenses
R&D Expense	135.8M	135.8M	109.4M	152.4M	276.7M
SG&A Expense	383.5M	383.5M	323.4M	275.3M	213.0M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	5.4M	—	17.7M	11.6M	13.0M
Total Operating Expenses	524.7M	519.3M	450.5M	439.2M	502.8M
Cost and Expenses	601.4M	599.7M	503.4M	476.6M	541.4M
Operating Income (EBIT)	32.8M	34.5M	24.9M	(77.2M)	(212.1M)
Non-Operating
Interest Income	3.3M	3.3M	5.4M	7.1M	3.0M
Interest Expense	46.2M	46.2M	49.6M	50.1M	37.1M
Net Interest Income	(42.8M)	(42.8M)	(44.2M)	(43.1M)	(34.1M)
Other Non-Op Income/Expense	(32.6M)	(34.3M)	(53.6M)	(72.9M)	(29.9M)
Non-Operating Income (excl Interest)	(13.6M)	(11.9M)	4.0M	22.7M	(7.2M)
EBT (Pre-Tax Income)	191.0K	191.0K	(28.8M)	(150.1M)	(242.0M)
Income Tax Expense	27.3M	27.3M	27.4M	1.5M	(5.5M)
Bottom Line
Net Income	(27.1M)	(27.1M)	(56.1M)	(151.6M)	(236.6M)
Earnings from Cont. Ops	(27.1M)	(27.1M)	(56.1M)	(151.6M)	(236.6M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(27.1M)	(27.1M)	(56.1M)	(151.6M)	(236.6M)
Per Share
Basic EPS	($0.09)	($0.09)	($0.18)	($0.51)	($0.82)
Diluted EPS	($0.09)	($0.09)	($0.18)	($0.51)	($0.82)
Revenue Per Share	$2.05	$2.06	$1.74	$1.35	$1.14
Shares
Basic Shares Outstanding	309.0M	308.4M	304.4M	295.2M	289.1M
Diluted Shares Outstanding	314.4M	308.4M	304.4M	295.2M	289.1M
Profitability Metrics
EBITDA	53.8M	53.8M	29.4M	(92.1M)	(199.6M)
D&A	7.5M	7.5M	8.5M	7.9M	5.3M
EBIT	46.4M	46.4M	20.8M	(100.0M)	(204.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025